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A novel somatostatin analogue, TT-232 (which inhibits the proliferation of various cell cultures and transplantable mouse tumours),
was examined regarding its effect on human melanoma and lymphoma xenografts as a single treatment or in combination with DTIC
(dacarbazine) and etoposide. TT-232 inhibited the growth of HT-18 melanoma xenografts, a dose of 5mgkg
1 being the most
effective. Combination of 1mgkg
1 TT-232 with 30 or 60mgkg
1 DTIC (administered daily) resulted in a stronger inhibitory effect
compared to TT-232 or DTIC as a single modality. Antimetastatic effect of TT-232 treatment combined with DTIC was studied using
the B16 mouse melanoma muscle – lung metastasis model. The number of lung metastases of B16 melanoma could be decreased by
the daily administration of 1mgkg
1 TT-232 or 60mgkg
1, but not of 30mgkg
1 DTIC. TT-232, combined with 30 or 60mgkg
1
DTIC decreased the lung metastasis number significantly lower than the control. Nearly 50% growth inhibition of HT-58 lymphoma
was achieved by daily treatment with 1mgkg
1 TT-232. 5mgkg
1 etoposide, administered daily, resulted in a similar effect. The
combination of 1mgkg
1 TT-232 and 5mgkg
1 etoposide was significantly more effective than TT-232 or etoposide as a single
treatment. The very strong tumour growth inhibitory effect of 10mgkg
1 etoposide could even be increased by combination with
TT-232. These experimental data suggest that TT-232 may be an effective new tool in the combination chemotherapy of malignant
tumours like melanoma and lymphoma.
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A novel somatostatin analogue of a five-residue ring structure D-
Phe-Cys-Tyr-D-Trp-Lys-Cys-Thr-NH2 (TT-232) has been studied
for its antiproliferative activity by our group. TT-232 showed a
strong antitumour effect both in vitro and in vivo. TT-232 was
effective on transplanted animal tumours (COLO 26, B16 melano-
ma, S180 sarcoma) and on human tumour xenografts (MDA-MB-
231 human breast cancer, PC-3 human prostate cancer). It was a
very important and promising finding that TT-232 proved to be
very effective in the D-10 melanoma model (Ke ´ri et al, 1996; Tejeda
et al, 1999; Schwab et al, 2001). In addition, TT-232 had practically
no growth hormone release inhibitory activity either in superfused
rat pituitary cells or in rats in vivo (Ke ´ri et al, 1993a,b, 1996), while
the application of various other somatostatin analogues (Robbins,
1996; Schally, 1988; Janecka et al, 2001) in tumour therapy is
limited because of their endocrine side effects (Setyono-Han et al,
1987). TT-232 was shown to be a potent inducer of apoptosis in a
wide array of cancer cell lines in vitro and in animal models in
vivo. On the other hand, it does not appear to produce the
endocrine effects of the natural compound (Ke ´ri et al, 1996). The
peptide acts via short-term induction of tyrosine phosphatases and
inhibition of tyrosine kinases: these two effects are most probably
independent of each other (Va ´ntus et al, 1995, 2001). We
demonstrated that early transient activation of Erk/MAPK is
important for the induction of cell cycle arrest and that activation
of the Erk/MAPK pathway by TT-232 involves PI 3-kinase, PKCd
and the protein tyrosine phosphatase a (PTPa) (Steta ´k et al,
2001b). Moreover, we demonstrated interaction of PI 3-kinase and
PKCd with PTPa and showed that the tyrosine phosphatase plays a
role in the activation of MAPK (Steta ´k et al, 2001a). Intracellular
target molecules, like the KU-86 protein, have been investigated in
the TT-232 mechanism of action, but unlike for octreotide, intra-
cellular distribution was not altered after treatment, suggesting a
p53-independent apoptotic mechanism. (To ´va ´ri et al, 1998).
In vivo data obtained so far proved selectivity of TT-232
concerning its antitumour activity: there was no bone marrow
suppression, or sign of any toxicity including weight loss of
experimental animals even in doses exceeding the therapeutic
dosage (Ke ´ri et al, 1996; Tejeda et al, 1999, 2000; Schwab et al,
2001). These observations suggest that somatostatin analogues
may be of value in the treatment of various human tumours,
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used antitumour drugs.
In order to study this therapeutic potential, two different
tumour lines and two different anticancer drugs were used in our
experiments to be presented. Since TT-232 proved to be effective
against melanoma, HT-18 human melanoma xenograft was chosen
as one of the experimental models. The known anticancer drug in
this case was dacarbazine (DTIC) (Wagner et al, 2000). The other
chemotherapeutic agent was etoposide, which has a different
mechanism of action, that is, it induces apoptosis (Hauke and
Armitage, 2000). Etoposide is generally used in the therapy of
lymphomas, therefore a human lymphoma xenograft, HT-58, was
used.
MATERIALS AND METHODS
Animals and animal-keeping conditions
Inbred, 8-week-old male CBA mice (Charles River Ltd, Hungary)
were used in the experiments applying human tumour xenografts.
Inbred, 8-week-old male C57Bl/6 mice (Charles River Ltd.,
Hungary) were used for inoculating B16 melanoma. The animals
were housed in an airconditioned, specific pathogen-free Animal
Care Facility in our department under controlled humidity
(5575%) and temperature (23721C). They were caged (5 per
cage) in polyethylene boxes and had free access to CRLTN
standard pelleted laboratory rodent chow (Charles River Ltd,
Hungary) and tap water.
All animal experiments have been performed following the
requirements (243/1998. XII. 31.) of the Hungarian Government,
and after permission of the Animal Welfare Controlling Office,
Budapest, Hungary (No 25-133/2001), meeting the standards
required by the UKCCCR guidelines (Workman et al, 1998).
Tumours
The human malignant melanoma HT-18 (ATCC CCL 121) cell line
was obtained from NIH/NCI, Bethesda, MD, USA; the human B-
cell lymphoma cell line HT-58 was established in our department
(Kopper et al, 1991). All cell lines were maintained in culture at the
Cell Culture Laboratory of our department. Cultured cells (210
6)
in log phase were inoculated subcutaneously into immunodeprived
mice (see below) and the subcutaneously growing tumours were
further transplanted three times in 3 week intervals. Experiments
were started from the fourth passage of the tumours.
The transplantable mouse melanoma line B16 was obtained
from the Institut fu ¨r Tumorbiologie und Krebsforschung, Uni-
versita ¨t Wien, Austria (courtesy Dr W Bursch) and maintained by
serial transplantation at our Animal Care Facility, by intramus-
cular injection of 10
5 suspended tumour cells into the muscles of
the right thigh.
Preparation of immunodeprived mice and tumour
inoculation
The 8-week-old male CBA mice were thymectomised by suction
thymectomy. After 8 days, 6Gy whole-body irradiation was given;
followed within 24h by homologous bone marrow transplantation.
At day 23 after thymectomy, 210
6 tumour cells were inoculated
subcutaneously (Figure 1).
Compounds administered
TT-232 (D-Phe-Cys-Tyr-D-Trp-Lys-Cys-Thr-NH2) is the product of
our Laboratory. DTIC (Dacarbazine), an alkylating agent with
inhibitory effect on purine synthesis, was obtained from Lachema,
Brno, Czech Republic. The ampoules contained 100mg DTIC in
powder form. Etoposide, a semisynthetic podophyllotoxine
derivative, was purchased from EVA, Haarlem, The Netherlands.
The ampoules contained 200mg etoposide in 10mg sterile
parenteral solution.
Treatment schedule
Experiment 1 (HT-18 melanoma, TT-232 treatment) Treatment
with TT-232 (0.2 – 1.5mgkg
1 body weight) was started on day 31
after thymectomy. TT-232 was dissolved in 0.9% sodium chloride
and DMSO mixture (20:1) and applied daily subcutaneously in
aliquots of 0.2ml. Control mice received only the solvent in
aliquots of 0.2ml s.c.
Experiment 2 (HT-18 melanoma, TT-232 and DTIC treatment)
Treatment with TT-232 (1mgkg
1 body weight) was started on
day 31 after thymectomy. Dissolution and application as in
Experiment 1.
DTIC administration was started the same day as TT-232. DTIC
was dissolved in 3% mannitol.
(Animals CBA, 8 weeks old ~ 20g)
08 92 3
days
Thymectomy
(suction)
6 Gy whole
body irradiation
Parameters: tumour volume
                      body weight periodically
                      tumour weight
Homologous
bone marrow
transplantation
Start of treatment,
repeated daily
s.c. = subcutaneous
31 3_4 weeks  ⇒
Sacrifice
2×10
6 tumour
cell inoculation 
s.c.
Figure 1 Experiment with human tumour xenografts on immunodeprived mice.
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British Journal of Cancer (2003) 88(1), 132–136 & 2003 Cancer Research UKThe daily dose of DTIC was 30mgkg
1 body weight and
60mgkg
1 body weight, respectively. DTIC was administered i.p.
The following groups of 10 were studied: Control (treated i.p. with
solvent only), TT-232 (1mgkg
1), DTIC (30mgkg
1), DTIC
(60mgkg
1), TT-232 (1mgkg
1) + DTIC (30mgkg
1), TT-232
(1mgkg
1) + DTIC (60mgkg
1).
Follow-up and termination of the experiments with
xenografts
Body weight was regularly determined at 4- to 6-day intervals
throughout the experiment. The experiments were terminated on
day 53 by exsanguination under Nembutal anaesthesia. Blood
serum was preserved for other studies (not presented here). Body
and tumour mass as well as tumour volume (measuring two
diameters using a caliper square) was recorded in order to avoid
occasional discrepancies between the values obtained by one of
these methods. The tumour tissues of all animals were fixed for
histological examination (to be reported).
Statistical analysis of the data on body mass, tumour volume
and tumour mass was performed using Student’s t-test. In all, 10
mice/group were used in all experiments for each dose and for the
solvent-treated controls.
Experiment 3 (B16 melanoma, TT-232 and DTIC treatment) The
B16 melanoma cells were inoculated intramuscularly (see above).
In summary, 24h after tumour inoculation treatment was started
and repeated daily until day 20 after tumour inoculation. At this
point in time the experiment was terminated by exsanguination
under Nembutal anaesthesia. Body masses and weight of the
primary, intramuscularly growing tumour were measured. The
lungs were fixed in Bouin’s fixative and the number of lung
metastases was counted under an inverted stereo microscope
2 days later (Figure 2). The following doses, in aliquots of
0.2ml, were used: TT-232, 1mgkg
1 body weight subcutaneously;
DTIC, 30mgkg
1 body weight intraperitoneally; DTIC, 60mgkg
1
body weight intraperitoneally. The following groups were
formed: TT-232 (1mgkg
1), DTIC (30mgkg
1), DTIC
(60mgkg
1), TT-232 (1mgkg
1) + DTIC (30mgkg
1), TT-232
(1mgkg
1) + DTIC (60mgkg
1). Dissolution and application as
in Experiments 1 and 2. Controls were treated subcutaneously,
daily with 0.2ml solvent (see above). In all, 10 mice were used for
all doses and the control. Student’s t-test was used for statistical
analysis.
Experiment 4 (HT-58 lymphoma, TT-232 and etoposide treat-
ment) Treatment with TT-232 (1mgkg
1 body weight) was
started on day 27 after thymectomy. Dissolution and application as
in Experiment 1. Etoposide administration was started the same
day as that of TT-232. Etoposide was dissolved in 0.9% sodium
chloride. The dose of etoposide was 5 and 10mgkg
1 body weight,
respectively. Etoposide was administered daily i.v. The following
groups were formed: control (treated subcutaneously with the
solvent only), TT-232 (1mgkg
1), etoposide (5mgkg
1), etopo-
side (10mgkg
1), TT-232 (1mgkg
1) + etoposide (5mgkg
1),
TT-232 (1mgkg
1) + etoposide (10mgkg
1).
RESULTS
Experiment 1 (HT-18 melanoma, TT-232 treatment)
As shown in Table 1, TT-232 inhibited the growth of HT-18 human
melanoma xenografts, reflected in tumour volume and tumour
weight at termination of the experiment. The strongest inhibition
was observed after the administration of 5mgkg
1 TT-232 (50%),
but the two lower doses also retarded tumour growth, although not
significantly (approximately to the same extent, 30%). Based on
the data of our previous experiments (Ke ´ri Gy et al, 1966; Tejeda
et al, 1999; Schwab et al, 2001) the dose of 1mgkg
1 was selected
for experiments when TT-232 was applied in combination with
other compounds.
days
0 12 0
Sacrifice
Start of treatment,
repeated daily
Parameters: tumour weight
                      lung metastasis number
i. m. = intramuscularly
106 tumour cells i.m.
into thigh muscle
(Animal: C57 Bl/6, 8 weeks old, ~ 20 g)
Figure 2 Experiment with B16 mouse melanoma.
Table 1 Effect of TT-232 treatment on tumour weight and tumour volume of HT-18 melanoma xenografts
Dose of TT-232
Control 0.2mgkg
1 1.0mgkg
1 5.0mgkg
1
Tumour weight (g) (mean7s.d.) 0.8870.33 0.5470.44 0.5570.35 0.4470.24*
Tumour volume at termination (mm
3) (mean7s.d.) 217.45738.51 199.09782.67 171.00797.8 138.42759.99**
*Po0.003 vs control, **Po0.002 vs control.
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British Journal of Cancer (2003) 88(1), 132–136 & 2003 Cancer Research UKExperiment 2 (HT-18 melanoma, TT-232 and DTIC
treatment)
The results of these experiments are summarised in Table 2.
Interestingly, there was no difference between the effects of 30
and 60mgkg
1 DTIC. A measure of 1mgkg
1 TT-232 exerted an
inhibitory effect in the same range observed in Experiment 1. The
combination of TT-232 with DTIC resulted in a stronger effect
compared to either TT-232 or DTIC alone. Both doses of DTIC, in
combination with TT-232, resulted in an equal degree of tumour
growth retardation (62 – 63%) showing significant difference from
the control.
Experiment 3 (B16 melanoma, TT-232 and DTIC treatment)
The growth of the intramuscularly growing primary B16 melanoma
could only be retarded to a certain degree in the groups treated
with 30 or 60mgkg
1 DTIC. No difference occurred between the
effect of the two doses and the addition of TT-232 did not increase
the effect of DTIC on the primary tumour. However, the number of
lung metastases was markedly decreased in the TT-232-treated
animals compared to the controls. This effect equalled that of
60mgkg
1 DTIC, whereas 30mgkg
1 DTIC was ineffective. When
TT-232 was combined with 30 or 60mgkg
1 DTIC, the metastasis
number decreased to a value that was significantly lower compared
to the controls (Table 3).
Experiment 4 (HT-58 lymphoma, TT-232 and etoposide
treatment)
The results shown in Table 4 point to the fact that nearly 50%
tumour growth inhibition could be achieved by 1mgkg
1 TT-232
treatment. A measure of 5mgkg
1 etoposide resulted in a similar
effect and the combination of TT-232 and 5mgkg
1 etoposide was
significantly more effective than TT-232 or etoposide as a single
treatment. In total, 10mgkg
1 etoposide alone inhibited tumour
growth very strongly, but this effect could even be increased by the
combination of 10mgkg
1 etoposide with 1mgkg
1 TT-232.
DISCUSSION
Our experiments showed that even TT-232 monotherapy inhibited
significantly the growth of HT-18 melanoma. Combination of
TT232 with DTIC resulted in a significant antiproliferative effect
compared to the control. Similarly, the lung metastasis number of
B16 melanoma could be decreased to a value significantly lower
than the control by TT-232 combined with DTIC, in relatively low
daily doses. Similar results were registered when HT-58 lympho-
ma-bearing mice were treated with TT-232 alone or in combina-
tion with etoposide. The 1mgkg
1 dose of TT-232 proved to be
less effective than 5mgkg
1, but was selected for combination
studies in order to find out whether the marginal effect exerted by
this dose can be enhanced by combination with other compounds.
DTIC is an alkylating agent that inhibits purine synthesis
(Wagner et al, 2000). Etoposide, a semisynthetic derivative of
podophyllotoxine is an inhibitor of DNA synthesis and acts in the
S and G1 phase of the cell cycle (Moskowity et al, 1999; Mugitani
et al, 1999). Both compounds are used in the therapy of human
lymphomas, but DTIC is primarily applied against malignant
melanomas. In our experiments, particularly in Experiment 2, the
tumour growth inhibitory effect of DTIC was moderate. The lack of
difference between the effect of 30 and 60mg of DTIC in
Experiment 2 may be explained by the possible suppressing effect
of the higher dose on the cellular immune response of the mice
thereby preventing cytotoxic lymphocytes to support the effect of
the cytotoxic drug.
Our group and others have recently studied the mode of action
of TT-232. The somatostatin analogue, TT-232, inhibits cell
proliferation and induces apoptosis in a variety of tumour cells
both in vivo and in vitro. As a result of the short half-life of the
natural somatostatin, analogues were designed to enable clinical
application. Introducing amino acids with ‘D’ configuration
resulted in compounds much more resistant to tissue proteases,
the major source of elimination of the natural peptide (Patel et al,
1996). This is characteristic for the structure of all commercially
available analogues and TT-232 as well. A number of these drugs,
in turn, proved selectivity for different receptor subtypes of the
somatostatin receptor family, which was associated with a marked
difference in the 3D structure, while TT-232 had a unique 3D
structure as was demonstrated by NMR studies (Ke ´ri et al, 1993b;
Jaspers et al, 1994).
We demonstrated the binding of the somatostatin analogue TT-
232 to plasma membranes either in vitro (Szegedi et al, 1999) or
in vivo with [
3H]-TT-232. Moreover, selective binding of TT-232 to
Table 2 Effect of TT-232 and DTIC treatment on tumour weight and
tumour volume of HT-18 melanoma xenografts
Tumour
weight (g)
Tumour volume at
termination (mm
3)
Treatment (mean7s.d.) (mean7s.d.)
Control 1.8871.28 253.87787.9
TT-232 1mgkg
1 1.2071.16 227798.15
DTIC 30mgkg
1 0.9070.96 206.5758.44
DTIC 60mgkg
1 0.8270.77 235.377127.04
TT-232 1mgkg
1+DTIC 30mgkg
1 0.6970.72* 207.147123.28
TT-232 1mgkg
1+DTIC 60mgkg
1 0.6870.46** 168.117116.26
*Po0.02 vs control, **Po0.01 vs control.
Table 3 Effect of TT-232 and DTIC treatment on the primary tumour
weight and lung metastasis number of B16 mouse melanoma
Tumour
weight (g)
Metastasis
number
Treatment (mean7s.d.) (mean7s.d.)
Control 4.970.9 9.779.4
TT-232 1mgkg
1 4.771.1 4.674.8
DTIC 30mgkg
1 3.871.1* 7.077.1
DTIC 60mgkg
1 3.670.7** 4.2874.95
TT-232 1mgkg
1+DTIC 30mgkg
1 4.070.6* 2.1671.32*****
T-232 1mgkg
1+DTIC 60mgkg
1 3.671.0**** 2.271.7*****
*Po0.03 vs control, **Po0.002 vs control and 0.01 vs TT-232 1mgkg
1,
****Po0.01 vs control, *****Po0.02 vs control.
Table 4 Effect of TT-232 and etoposide on the tumour weight and
tumour volume of HT-58 lymphoma xenografts
Tumour
weight (g)
Tumour volume at
termination (mm
3)
Treatment (mean7s.d.) (mean7s.d.)
Control 0.7370.33 1947142
TT-232 1mgkg
1 0.3870.14* 58748*
Etoposide 5mgkg
1 0.2870.25** 56733*
Etoposide 10mgkg
1 0.0570.03*** 1474**
TT-232 1mgkg
1+etoposide 5mgkg
1 0.1770.03** 34733**
TT-232 1mgkg
1+etoposide 10mgkg
1 0.0270.0*** 1270***
*Po0.05 vs control, **Po0.01 vs control and 0.01 vs TT-232 1mgkg
1,
***Po0.002 vs control.
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British Journal of Cancer (2003) 88(1), 132–136 & 2003 Cancer Research UKsomatostatin receptor subtypes 1 (IC50 713nM) and 5 (IC50 564nM)
has also been shown in vitro (Steta ´k et al, 2001b) suggesting a
receptor-mediated signalling mechanism. This finding is sup-
ported by the facts that TT-232 is a structural analogue of
somatostatin, that the early signalling pathway of TT-232 is
pertussis toxin sensitive, and several signalling elements are
common between TT-232 and somatostatin. However, longer
treatment by the compound leads to strong induction of apoptosis,
which appears to be independent of early signaling events, and
requires endocytosis (Va ´ntus et al, 2001). This suggests a dual
effect of TT-232 on cells, including an early signalling cascade via
somatostatin receptors, and a second, later event through a so far
unidentified pathway.
One of the early effects of the somatostatin analogue TT-232 is
the rapid activation of protein tyrosine phosphatases and the
induction of cell cycle arrest via the increase of p21
Cip1/Waf1 levels
(Steta ´k et al, 2001b). This antiproliferative activity is mediated
through a signaling pathway involving PI 3-kinase, pp60
c-src kinase
and MAP-kinase (Steta ´k et al, 2001a).
Combination of anticancer compounds with different modes of
action is widely used in the therapy of malignancies. Since the
chemotherapy of malignant melanoma is still unsolved (Van der
Esch et al, 1981; Ak et al, 2000) and the situation is similar in the
case of most lymphomas (Hauke and Armitage, 2000; Kluin-
Nelemans et al, 2001), new therapeutic modalities are needed. Our
experiments indicate that TT-232 could be successfully used in
combination chemotherapy of melanomas and lymphomas, and
probably also of other malignant tumours.
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